Effectiveness Of Atomoxetine For Cognitive Function In Methamphetamine Dependent Patients; A Randomized Controlled Trial
International Journal of Medical Toxicology and Forensic Medicine,
20 September 2021
Background: A substantial body of evidences indicates that methamphetamine abuse can lead to persistent and serious cognitive dysfunction. Preclinical studies and early pilot clinical investigations have suggested that atomoxetine, a cognitive enhancer may be useful in improving of cognitive dysfunction. The present study evaluated whether atomoxetine would effect on cognitive dysfunction in methamphetamine dependent patients.
Methods: Participants with methamphetamine dependence (N =86) which were on methadone maintenance therapy (MMT) were enrolled in a double-blind, placebo-controlled randomized clinical trial. This investigation was performed on 86 subjects to consume either 40 mg/day atomoxetine (n = 45) or placebo (n = 41) for 8 weeks. Between January 2016 and June 2017, volunteers were selected from methamphetamine abusers in MMT centers in Kashan, Iran. They completed at the first and each monthly visit the Cognitive Abilities Questionnaire for assessing the cognitive functions. The data were analyzed using Independent sample t test, Mann Whitney test and chi square with SPSS version 20.0.
Results: This study revealed that, atomoxetine treatment improved some of the cognitive dysfunctions in methamphetamine users including memory, inhibitory control, selective attention, decision making, planning, sustained attention, and cognitive flexibility in methamphetamine users (p<0.05), but the social cognition improvement was less than others (p=0.107). There were only mild side effects in placebo and atomoxetine groups.
Conclusions: The findings show the efficacy of atomoxetine for improving the cognitive dysfunction in methamphetamine users and suggest potential efficacy of atomoxetine for treating them.
- Cognitive effects
How to Cite
2. Davidson C, Gow AJ, Lee TH, Ellinwood EHJBRR. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. 2001;36(1):1-22.
3. Nakagawa T, Kaneko SJJops. Neuropsychotoxicity of abused drugs: molecular and neural mechanisms of neuropsychotoxicity induced by methamphetamine, 3, 4-methylenedioxymethamphetamine (ecstasy), and 5-methoxy-N, N-diisopropyltryptamine (foxy). 2008;106(1):2-8.
4. Salo R, Nordahl TE, Possin K, Leamon M, Gibson DR, Galloway GP, et al. Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals. 2002;111(1):65-74.
5. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJJHrop. Implications of chronic methamphetamine use: a literature review. 2005;13(3):141-54.
6. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. 2007;17(3):275-97.
7. Burgess PW, Veitch E, de Lacy Costello A, Shallice TJN. The cognitive and neuroanatomical correlates of multitasking. 2000;38(6):848-63.
8. Damasio ARJTN. REVIEW: Toward a Neurobiology of Emotion and Feeling: Operational Concepts and Hypotheses. 1995;1(1):19-25.
9. Grafman J, Litvan IJTL. Importance of deficits in executive functions. 1999;354(9194):1921-3.
10. Stuss DT, Shallice T, Alexander MP, Picton TWJAotNYaos. A Multidisciplinary Approach to Anterior Attentional Functions a. 1995;769(1):191-212.
11. Ornstein T, Iddon J, Baldacchino A, Sahakian B, London M, Everitt B, et al. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. 2000;23(2):113-26.
12. Saxon A, Straits-Troster K, Rippeth J, Romwall L, Rosenbaum G, Bush K, editors. Longitudinal cognitive changes among methamphetamine dependent patients in early abstinence. annual meeting of College on Problems of Drug Dependence, Bal Harbour, FL; 2003.
13. L. Simon CD, Jennifer Carnell, Paul Brethen Brethen, Richard Rawson, Walter Ling, Sara %J American Journal on Addictions. Cognitive impairment in individuals currently using methamphetamine. 2000;9(3):222-31.
14. Volkow ND, Chang L, Wang G-J, Fowler JS, Franceschi D, Sedler M, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. 2001;21(23):9414-8.
15. Volkow ND, Chang L, Wang G-J, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. 2001;158(3):377-82.
16. Fredriksen M, Halmøy A, Faraone SV, Haavik JJEN. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. 2013;23(6):508-27.
17. Simpson D, Plosker GLJD. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. 2004;64(2):205-23.
18. Rabiey A, Hassani-Abharian P, Farhad M, Moravveji AR, Akasheh G, Banafshe HR. Atomoxetine Efficacy in Methamphetamine Dependence during Methadone Maintenance Therapy. Archives of Iranian medicine. 2019;22(12):692-8.
19. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. 2002;27(5):699-711.
20. Nejati VJAiCS. Cognitive abilities questionnaire: Development and evaluation of psychometric properties. 2013;15(2):11-9.
21. Sofuoglu M, Poling J, Hill K, Kosten TJTAjod, abuse a. Atomoxetine attenuates dextroamphetamine effects in humans. 2009;35(6):412-6.
22. DeVito EE, Herman AI, Konkus NS, Zhang H, Sofuoglu MJPB, Behavior. Atomoxetine in abstinent cocaine users: cognitive, subjective and cardiovascular effects. 2017;159:55-61.
23. Cantilena L, Kahn R, Duncan CC, Li S-H, Anderson A, Elkashef AJJoam. Safety of atomoxetine in combination with intravenous cocaine in cocaine-experienced participants. 2012;6(4):265.
24. Stoops WW, Blackburn JW, Hudson DA, Hays LR, Rush CRJD, dependence a. Safety, tolerability and subject-rated effects of acute intranasal cocaine administration during atomoxetine maintenance. 2008;92(1-3):282-5.
25. Han DD, Gu HHJBp. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. 2006;6(1):1-7.
26. Vanderschuren LJ, Beemster P, Schoffelmeer ANJP. On the role of noradrenaline in psychostimulant-induced psychomotor activity and sensitization. 2003;169(2):176-85.
27. Szabo ST, Blier PJEJoN. Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. 2001;13(11):2077-87.
- Abstract Viewed: 42 times
- PDF Downloaded: 10 times